title: Letter: Effectiveness of split-dose certolizumab pegol for Crohn's disease.
authors.affiliation: Department of Gastroenterology, Mayo Clinic, Rochester, MN, USA. sunandakane.apt@gmail.com.
authors.forename: S V
authors.initials: SV
authors.lastname: Kane
authors.forename: B
authors.initials: B
authors.lastname: Neis
authors.forename: B D
authors.initials: BD
authors.lastname: Becker
authors.forename: D
authors.initials: D
authors.lastname: Bruining
authors.forename: W A
authors.initials: WA
authors.lastname: Faubion
authors.forename: J
authors.initials: J
authors.lastname: Kisiel
authors.forename: E V
authors.initials: EV
authors.lastname: Loftus
authors.forename: D
authors.initials: D
authors.lastname: Pardi
authors.forename: L
authors.initials: L
authors.lastname: Raffals
authors.forename: K
authors.initials: K
authors.lastname: Schroeder
authors.forename: W J
authors.initials: WJ
authors.lastname: Tremaine
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068582:Certolizumab Pegol; D003424:Crohn Disease / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage*; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D007166:Immunosuppressive Agents; D011092:Polyethylene Glycols; D000068582:Certolizumab Pegol